ST葫芦娃：“磷酸奥司他韦干混悬剂”等产品取得注册证

Group 1 - ST HuLuWa announced the approval of drug registration certificates for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution by the National Medical Products Administration [1] - The company's revenue composition for the year 2024 is projected to be 100% from the pharmaceutical manufacturing industry [1] - As of the report, ST HuLuWa has a market capitalization of 3.7 billion yuan [1] Group 2 - The announcement highlights a significant breakthrough in drug development, recognized by both Chinese and American authorities for its therapeutic efficacy [1]